Skip to main content
. 2018 Nov 14;12(2):269–281. doi: 10.1016/j.tranon.2018.09.015

Supplementary Figure 4.

Supplementary Figure 4

Drug response to activation of p53, the acetylated p53.

Western blot analysis of GS11-079 PDC and LPS246, liposarcoma cell line. Cells were treated with bortezomib (0-80 μM) for 48 hours. Lysates were subjected to an analysis of the anticancer effect of bortezomib in response to p53, p21 pathway.